SI1713813T1 - Polimorfne oblike agonista gabaa - Google Patents

Polimorfne oblike agonista gabaa

Info

Publication number
SI1713813T1
SI1713813T1 SI200530521T SI200530521T SI1713813T1 SI 1713813 T1 SI1713813 T1 SI 1713813T1 SI 200530521 T SI200530521 T SI 200530521T SI 200530521 T SI200530521 T SI 200530521T SI 1713813 T1 SI1713813 T1 SI 1713813T1
Authority
SI
Slovenia
Prior art keywords
polymorphic forms
gabaa agonist
gabaa
agonist
polymorphic
Prior art date
Application number
SI200530521T
Other languages
English (en)
Slovenian (sl)
Inventor
Vincent Brett Cooper
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1713813(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of SI1713813T1 publication Critical patent/SI1713813T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200530521T 2004-01-30 2005-01-28 Polimorfne oblike agonista gabaa SI1713813T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0402118.4A GB0402118D0 (en) 2004-01-30 2004-01-30 Polymorphic forms of a GABAA agonist
PCT/GB2005/000288 WO2005073237A2 (en) 2004-01-30 2005-01-28 Polymorphic forms of a gabaa agonist
EP05702040A EP1713813B1 (en) 2004-01-30 2005-01-28 Polymorphic forms of a gabaa agonist

Publications (1)

Publication Number Publication Date
SI1713813T1 true SI1713813T1 (sl) 2009-02-28

Family

ID=31971783

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200530521T SI1713813T1 (sl) 2004-01-30 2005-01-28 Polimorfne oblike agonista gabaa

Country Status (34)

Country Link
US (2) US7262300B2 (enExample)
EP (2) EP2042505A1 (enExample)
JP (1) JP4917440B2 (enExample)
KR (1) KR101210361B1 (enExample)
CN (1) CN1914212B (enExample)
AR (1) AR047511A1 (enExample)
AT (1) ATE414088T1 (enExample)
AU (1) AU2005209473B2 (enExample)
BR (1) BRPI0506858A (enExample)
CA (1) CA2554536C (enExample)
CO (1) CO5700743A2 (enExample)
CY (1) CY1108647T1 (enExample)
DE (1) DE602005010975D1 (enExample)
DK (1) DK1713813T3 (enExample)
DO (1) DOP2005000013A (enExample)
EA (1) EA009413B1 (enExample)
EC (1) ECSP066735A (enExample)
ES (1) ES2314613T3 (enExample)
GB (2) GB0402118D0 (enExample)
HR (1) HRP20080614T3 (enExample)
IL (1) IL176863A0 (enExample)
MA (1) MA28364A1 (enExample)
MX (1) MXPA06008595A (enExample)
MY (1) MY139525A (enExample)
NO (1) NO20063843L (enExample)
NZ (1) NZ548191A (enExample)
PE (1) PE20050769A1 (enExample)
PL (1) PL1713813T3 (enExample)
PT (1) PT1713813E (enExample)
SI (1) SI1713813T1 (enExample)
TW (1) TWI345972B (enExample)
UA (1) UA87487C2 (enExample)
WO (1) WO2005073237A2 (enExample)
ZA (1) ZA200605307B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
BRPI0520588B8 (pt) 2005-09-28 2021-05-25 Auris Medical Ag uso de composições farmacêuticas para o tratamento de doenças do ouvido interno
CN102093387B (zh) * 2009-12-10 2012-07-25 天津泰普医药知识产权流转储备中心有限公司 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
WO2013087090A1 (en) 2011-12-12 2013-06-20 Auris Medical Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
MX391708B (es) 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
AU2017363598A1 (en) * 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
KR20200047557A (ko) 2017-08-04 2020-05-07 오비드 테라퓨틱스 인크. 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용
KR20210062662A (ko) 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용
CN113395962A (zh) 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
AU2020405060A1 (en) 2019-12-18 2022-06-09 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) * 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4315934A (en) * 1979-09-24 1982-02-16 Sandoz Ltd. Organic compounds
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) * 1980-11-03 1982-10-05 Occidental Research Corporation Apparatus for selective wetting of particles
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
WO2001022941A1 (en) 1999-09-28 2001-04-05 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
MXPA03010610A (es) 2001-05-18 2004-04-02 Lonza Ag Metodo para la preparacion de formulaciones solidas de 3-hidroxi-3-metilbutirato de sodio.
CZ20033269A3 (en) 2001-05-21 2004-03-17 H. Lundbeck A/S Granular preparations of gaboxadol
AU2002333157A1 (en) * 2002-09-03 2004-03-29 Naturon Limited Compound for treatment of anxiety and methods of preparation and use thereof
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
EP2145620A3 (en) 2003-06-25 2010-03-17 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
EP1663218A1 (en) 2003-09-10 2006-06-07 MERCK SHARP & DOHME LTD. Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
CA2572302A1 (en) 2004-06-29 2006-05-26 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) * 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
EP1863808A1 (en) 2005-03-18 2007-12-12 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
EP1906953A4 (en) 2005-04-29 2009-05-20 Lundbeck & Co As H ACID AND BASE SALT FORMS OF GABOXADOL

Also Published As

Publication number Publication date
DOP2005000013A (es) 2005-08-15
CN1914212B (zh) 2010-10-06
HK1096547A1 (en) 2007-06-01
NZ548191A (en) 2010-04-30
PE20050769A1 (es) 2005-10-04
HRP20080614T3 (en) 2009-01-31
US20070259912A1 (en) 2007-11-08
PL1713813T3 (pl) 2009-04-30
KR101210361B1 (ko) 2012-12-10
MY139525A (en) 2009-10-30
TWI345972B (en) 2011-08-01
CN1914212A (zh) 2007-02-14
CY1108647T1 (el) 2014-04-09
GB0501847D0 (en) 2005-03-09
US7262300B2 (en) 2007-08-28
EA200601404A1 (ru) 2006-12-29
ZA200605307B (en) 2007-11-28
CA2554536C (en) 2012-09-18
JP4917440B2 (ja) 2012-04-18
PT1713813E (pt) 2008-12-26
WO2005073237A3 (en) 2005-10-20
BRPI0506858A (pt) 2007-05-29
UA87487C2 (ru) 2009-07-27
EA009413B1 (ru) 2007-12-28
ECSP066735A (es) 2006-10-31
EP2042505A1 (en) 2009-04-01
IL176863A0 (en) 2006-10-31
CO5700743A2 (es) 2006-11-30
KR20070007070A (ko) 2007-01-12
MXPA06008595A (es) 2006-08-28
AU2005209473B2 (en) 2010-03-04
MA28364A1 (fr) 2006-12-01
NO20063843L (no) 2006-08-29
US20050171142A1 (en) 2005-08-04
EP1713813A2 (en) 2006-10-25
JP2007519697A (ja) 2007-07-19
TW200534856A (en) 2005-11-01
US8236958B2 (en) 2012-08-07
WO2005073237A2 (en) 2005-08-11
DE602005010975D1 (de) 2008-12-24
EP1713813B1 (en) 2008-11-12
AR047511A1 (es) 2006-01-25
GB2410434A (en) 2005-08-03
ES2314613T3 (es) 2009-03-16
ATE414088T1 (de) 2008-11-15
GB0402118D0 (en) 2004-03-03
CA2554536A1 (en) 2005-08-11
DK1713813T3 (da) 2009-02-16
AU2005209473A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
TWI345972B (en) Polymorphic forms of a gabaa agonist
IL182580A0 (en) Polymorphic forms of 6-[2-
GB2444208B (en) Gripping assembly for expandable tubulars
ZA200905377B (en) Polymorphic forms of a macrocyclic inhibitor of HCV
EP1735702A4 (en) POLYMORPHIC REGULAR TERMS
IL180707A0 (en) Polymorphs of atomoxetine hydrochloride
IL181185A0 (en) Novel polymorphs of azabicyclohexane
EP1628664A4 (en) POLYMORPHIC FORMS OF NALTREXONE
EP1804582A4 (en) POLYMORPH SHAPES OF TADALAFIL
DK1667975T3 (da) En polymorf form for 3-phenylsulfonyl-8-piperazin-1-yl-quinolin
IL183235A0 (en) Method of making dorzolamide hydrochloride
GB0504314D0 (en) Novel polymorph
IL176953A0 (en) Polymorphic forms of nateglinide
EP1848420A4 (en) POLYMORPH SHAPES OF A GABAA AGONIST
EP1957657A4 (en) BIOMARKER OF ENHANCED INTESTINAL FUNCTION
GB0418529D0 (en) Method for analysing
SI1812422T1 (sl) Kristalna oblika irbesartana
IL180574A0 (en) Methods of detecting a phenotype of a polymorphic protein
GB0619888D0 (en) New polymorphic forms of pregabalin
IL185801A0 (en) Hydrocodone polymorphs
GB0411125D0 (en) Method of improving T-cell receptors
GB0406662D0 (en) Methods for identification of compounds that interact with receptors
GB0511461D0 (en) A method of analysis
GB0501725D0 (en) A method of analysis
GB0422262D0 (en) Method of gridlock resolution